Crossmark

The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types

Crossref DOI link: https://doi.org/10.1186/s12885-024-12812-7

Published Online: 2024-08-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nobin, Hampus

Garvin, Stina

Hagman, Helga

Nodin, Björn

Jirström, Karin

Brunnström, Hans
Funding

Funding for this research was provided by:

Lund University
License Information

Text and Data Mining valid from 2024-08-26

Version of Record valid from 2024-08-26
More Information

Article History

Received: 14 June 2024

Accepted: 14 August 2024

First Online: 26 August 2024

Declarations

:

: The study was approved by the Ethics Committee of Linköping, Sweden, and exempted from the rule of informed consent in their approval (2018/342 − 31).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below